Mobocertinib, sold under the brand name Exkivity, is used for the treatment of non-small cell lung cancer. The most common side effects include diarrhea...
15 KB (1,082 words) - 00:30, 21 March 2024
achieved a median overall survival of 30 months with pembrolizumab. Mobocertinib (Exkivity) was approved for medical use in the United States in September...
51 KB (5,333 words) - 22:13, 7 September 2024
Olmutinib L01EB07 Dacomitinib L01EB08 Icotinib L01EB09 Lazertinib L01EB10 Mobocertinib L01EB11 Aumolertinib L01EC01 Vemurafenib L01EC02 Dabrafenib L01EC03 Encorafenib...
12 KB (877 words) - 15:36, 25 January 2024
Aumolertinib Brigatinib Dacomitinib Erlotinib Gefitinib Icotinib Lazertinib Mobocertinib Olmutinib Osimertinib Rociletinib Vandetanib) HER1/EGFR and HER2/neu...
12 KB (808 words) - 05:25, 15 September 2024
Aumolertinib Brigatinib Dacomitinib Erlotinib Gefitinib Icotinib Lazertinib Mobocertinib Olmutinib Osimertinib Rociletinib Vandetanib) HER1/EGFR and HER2/neu...
12 KB (758 words) - 23:46, 14 March 2024
Therapeutics pruritis related to hemodialysis in chronic kidney disease Mobocertinib Takeda Pharmaceuticals non-small cell lung cancer with EGFR exon 20 insertion...
34 KB (180 words) - 22:09, 8 April 2024
appendix) cancer. The second generation EGFR inhibitors Afatinib and Mobocertinib have been approved for the treatment of EGFR driven lung cancer and Dacomitinib...
20 KB (2,061 words) - 05:47, 29 November 2023